News

Photo

CEFIC Calls for a Strengthened EU Single Market

CEFIC, the European Chemical Industry Council, together with 25 other regional industry associations, has issued a joint statement calling on the European Union (EU) to realize the true potential of the single market.

Photo

Maire Tecnimont Awarded Green Hydrogen & Ammonia Plant Design Contract

Maire Tecnimont has been awarded a FEED contract by MadoquaPower2X to develop an integrated green hydrogen and green ammonia plant located in the industrial zone of Sines, Portugal. MadoquaPower2x is a consortium comprised of Madoqua Renewables, Power2X, and Copenhagen Infrastructure Partners (CIP), through its Energy Transition Fund.

Photo

Air Liquide and Dow Renew Supply Deal for German Site

Air Liquide and Dow renewed their industrial gas supply agreement for Dow’s chemical production site in Stade, Germany. Under the long-term agreement, Air Liquide will supply industrial gases and invest almost €40 million in modernizing its facilities to increase operational efficiency and reduce CO₂ emissions.

Photo

LG Chem Inks Battery Material Supply Deal with GM

South Korean chemicals group LG Chem has secured a long-term cathode material supply contract with General Motors (GM), worth KRW 25 trillion (about $19 billion). LG Chem intends to use its US cathode plant in Tennessee as a production center for the global battery materials market.

Photo

AstraZeneca to Construct New US Cell Therapy Facility

In a move to launch its cell therapy platforms for critical cancer trials in the US, AstraZeneca is investing $300 million in a new facility in Rockville, Maryland. The site will initially focus on the production of T-cell therapies, with the possibility of supporting other disease areas in the future.

Photo

Novo Holdings to Acquire Catalent for $16.5 Billion

Novo Holdings, Novo Nordisk's parent company, is acquiring US contract development and manufacturing organization (CDMO) Catalent for $16.5 billion. The companies said that Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash.

Photo

Brenntag Acquires a Chemical Logistics Site in Italy

Brenntag announced the agreement to acquire a chemical logistics site of Chimica D’Agostino in Italy. The site is located in the industrial area of the city of Bari, well connected with Adriatic highway, and with easy access to harbours on the seaside.

Photo

Bertrand Piccard Unveils Climate Impulse

Swiss explorer Bertrand Piccard has revealed his latest project: an emission-free airplane powered by green hydrogen. The aircraft aims to achieve a non-stop flight around the Earth, showcasing practical solutions for a cleaner and more efficient world. Partnering with Syensqo, this technological and environmental adventure will push the boundaries of innovation. The airplane is being developed in France by engineer and navigator Raphaël Dinelli.

Photo

MSD Animal Health to Acquire Elanco’s Aqua Business

MSD Animal Health, a division of Merck & Co., announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for €1.2 billion ($1.3 billion) in cash. The acquisition is expected to be completed by mid-year 2024, subject to approvals from regulatory authorities and other customary closing conditions.

Photo

Siegfried Announces Changes in Senior Management Team

Siegfried has appointed Marianne Späne, currently chief business officer Drug Products, as chief business officer with responsibility for both the Drug Substances and Drug Products divisions of the Swiss contract manufacturing and development organization (CDMO), effective Feb. 1, 2024. Christian Dowdeswell, who previously led the Drug Substance business, has decided to leave Siegfried.

Photo

Teva Intends to Divest API Business

Israeli generics manufacturer Teva Pharmaceuticals intends to divest its active pharmaceutical ingredient (API) business, Teva API (TAPI). A standalone business unit of Teva, TAPI supplies APIs to over 1,000 customers worldwide and has approximately 4,300 employees worldwide.

Photo

Lonza and Oxford Nanopore to Collaborate on mRNA Analysis

Swiss contract development and manufacturing organization (CDMO) Lonza will collaborate with Oxford Nanopore Technologies, a UK-based company delivering a new generation of nanopore-based molecular sensing technology. The collaboration aims to cGMP validate and commercialize a first-of-its-kind novel test to accurately determine multiple critical quality attributes of mRNA products by directly sequencing both the DNA template and the messenger RNA (mRNA).

Photo

AbbVie to Build New Biologics Manufacturing Site in Singapore

Last week, AbbVie broke ground on a new Singapore manufacturing facility located in Singapore's Tuas Biomedical Park. The company will invest $223 million in the site which will add 24,000 l of biologics drug-substance capacity to AbbVie's global manufacturing network and support current products as well as emerging immunology and oncology compounds within its pipeline.

Photo

Gedeon Richter Becomes Strategic Investor of Formycon

Hungary-headquartered specialty pharmaceutical company Gedeon Richter becomes a strategic investor of German biosimilars company Formycon via cash capital increase of 9.08% of Formycon’s share capital, which corresponds to €82.84 million.

Photo

Olon to Open New High Potency API Suite in US

Olon Group is building a state-of-the-art High Potency Active Pharmaceutical Ingredient (HPAPI) suite at its Olon USA site in Concord, Ohio. This expands the company's capabilities for handling HPAPI, with investments totaling around €40 million ($43 million) in recent years.

Photo

Corbion to Divest Emulsifiers Business to Kingswood

Dutch ingredients producer Corbion has agreed to divest its emulsifier business to US private equity firm Kingswood Capital Management for $362 million. The transaction, which is expected to close in the second quarter of this year, is contingent upon the satisfaction of certain conditions, including regulatory approvals.

Photo

Sanofi to Acquire Inhibrx for $1.7 Billion

Sanofi agreed to acquire biopharmaceutical company Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx for approximately $1.7 billion and will also retain an 8% equity stake in New Inhibrx. Sanofi said that it expects to finance the transaction with available cash resources.

13060 more News

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.